BRITISH JOURNAL

OF

HAEMATOLOGY

EDITORS: IAN HANN, FINBARR COTTER, JOHN REILLY

ASSOCIATE EDITORS

B. Bennett, H. E. Broxmeyer, A. K. Burnett, R. Foa, M. Greaves, M. Y. Gordon,
I. R. Peake, M. J. Pippard, D. Provan, I. A. G. Roberts, N. Russell, S. L. Thein, L. Williamson

EDITORIAL BOARD

I. R. Peake *Chairman*

T. Baglin, B. J. Bain, Y. Beuzard, J. Boultwood, C. Camaschella, C. J. Eaves,
P. Fenaux, A. Goodeve, A. R. Green, J. D. Griffin, H. Heslop, T. L. Holyoake, M. Le Beau,
D. Linch, B. I. Lord, C. Mecucci, D. R. Miller, P. A. H. Moss, A. Nurden, G. Prentice,
D. Rund, O. P. Smith, T. Uchiyama, J. J. M. van Dongen, M. Worwood

Volume 120
Pages 1–1104

Blackwell
Publishing

2003

© 2003 *British Journal of Haematology* Blackwell Publishing Ltd
Published by Blackwell Publishing Ltd
Editorial Offices:
Blackwell Publishing Ltd, 23 Ainslie Place, Edinburgh EH3 6AJ, UK
Blackwell Publishing Ltd, 9600 Garsington Road, Oxford OX4 2DQ, UK
Blackwell Publishing Asia Pty, 550 Swanston Street, Carlton South, Melbourne, VIC 3053, Australia, and TK Building, 2-38-14 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
Blackwell Publishing Europe Ltd, 10 rue Casimir Delavigne, F-75006 Paris, France
Blackwell Verlag GmgH, Kurfürstendamm 57, D-10707 Berlin, Germany
Blackwell Publishing KK, MG Kodenmacho Building 3F, 7–10 Kodenmacho Nihombashi, Chuo-ku, Tokyo 103-0001, Japan
Blackwell Publishing Inc, Commerce Place, 350 Main Street, Malden, MA 02148-5018, USA

Authorization to photocopy items for internal or personal use is granted by the copyright holder for libraries and other users of the Copyright Clearance Center (CCC), 222 Rosewood Drive, Danvers, MA 01923, USA (www.copyright.com), provided the appropriate fee is paid directly to the CCC. This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works or for resale.

British Journal of Haematology is covered by *ADONIS, ASCA, Chemical Abstracts, Current Awareness in Biological Sciences, Current Contents, Current Clinical Cancer, Index Medicus, ISI/BIOMED,* and *Science Citation Index*.

ISSN 0007-1048

Typeset by Scientific Publishing Services, India, and printed by the Alden Group, Oxford.

BRITISH JOURNAL OF HAEMATOLOGY

Volume 120, Issue 1, January-I 2003

IMAGES IN HAEMATOLOGY

1 **Disseminated fusariosis in a patient with acute leukaemia**
H. Khoury and N. J. Ball

2 **Bone marrow cryptococcosis in a human immunodeficiency virus-negative patient**
S. Basu, N. Marwaha and V. Aggarwal

REVIEWS

3 **Tumour-associated antigens in multiple myeloma**
C. Pellat-Deceunynck

10 **Novel therapies for multiple myeloma**
T. Hayashi, T. Hideshima and K. C. Anderson

GUIDELINE

18 **Thalidomide in multiple myeloma: current status and future prospects**
J. D. Cavenagh and H. Oakervee on behalf of the UK Myeloma Forum and The BCSH Haematology/Oncology Task Forces

MULTIPLE MYELOMA

27 **Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte–macrophage colony-stimulating factor and interleukin 2 in a myeloma model**
J. Stritzke, T. Zunkel, J. Steinmann, N. Schmitz, L. Uharek and M. Zeis

36 **Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma**
F. Perosa, M. Prete, G. Luccarelli and F. Dammacco

44 **Prognostic impact of cytogenetic and interphase fluorescence *in situ* hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II**
J. Shaughnessy Jr, E. Tian, J. Sawyer, J. McCoy, G. Tricot, J. Jacobson, E. Anaissie, M. Zangari, A. Fassas, F. Muwalla, C. Morris and B. Barlogie

Short report 53 **Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM**
S. Uneda, H. Hata, F. Matsuno, N. Harada, Y. Mitsuya, F. Kawano and H. Mitsuya

HAEMATOLOGICAL MALIGNANCY

56 **Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study**
Y. Miyazaki, K. Kuriyama, S. Miyawaki, S. Ohtake, H. Sakamaki, T. Matsuo, N. Emi, T. Kobayashi, T. Matsushima, K. Shinagawa, R. Ohno and M. Tomonaga for the Japan Adult Leukaemia Study Group

63 **Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia**
K. Eisendle, A. Lang, B. Eibl, D. Nachbaur, H. Glassl, M. Fiegl, J. Thaler and G. Gastl

74 **Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia**
M. Krampera, A. Vitale, C. Vincenzi, O. Perbellini, A. Guarini, L. Annino, G. Todeschini, A. Camera, F. Fabbiano, G. Fioritoni, F. Nobile, R. Szydlo, F. Mandelli, R. Foà and G. Pizzolo

80 **Mu class glutathione S-transferase mRNA isoform expression in acute lymphoblastic leukaemia**
P. R. Kearns, Z. M. A. Chrzanowska-Lightowlers, R. Pieters, A. Veerman and A. G. Hall

Short reports

89 **FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia**
P. Arrigoni, C. Beretta, D. Silvestri, V. Rossi, C. Rizzari, M. G. Valsecchi, G. Cazzaniga and A. Biondi

93 **Common expression of an unusual CD45 isoform on T cells from patients with large granular lymphocyte leukaemia and autoimmune lymphoproliferative syndrome**
J. J. H. Bleesing, J. E. Janik and T. A. Fleisher

97 **High frequency of t(11;18) in gastric mucosa-associated lymphoid tissue lymphomas in Taiwan, including one patient with high-grade transformation**
S.-S. Chuang, C. Lee, R. A. Hamoudi, H. Liu, P.-S. Lee, H. Ye, T. C. Diss, A. Dogan, P. G. Isaacson and M.-Q. Du

PLATELETS, HAEMOSTASIS AND THROMBOSIS

101 **Identification of simultaneous mutation of fibrinogen α chain and protein C genes in a Japanese kindred**
K. Watanabe, A. Shibuya, E. Ishii, M. Kurihara, S. Inoue, M. Ono, Y. Wada, M. Wakiyama, M. Zaitsu, H. Iida, K. Muraoka, S. Kinoshita and N. Hamasaki

109 **Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial**
M. Cushman, J. P. Costantino, E. G. Bovill, D. L. Wickerham, L. Buckley, J. D. Roberts and D. N. Krag

117 **Acquired resistance to activated protein C in breast cancer patients**
M. R. Nijziel, R. van Oerle, M. Christella, L. G. D. Thomassen, E. C. M. van Pampus, K. Hamulyák, G. Tans and J. Rosing

123 **Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters?**
R. A. Bucek, M. Reiter, P. Quehenberger, A. Weltermann, P. A. Kyrle and E. Minar

129 **Plasma from patients with thrombotic thrombocytopenic purpura induces activation of human monocytes and polymorphonuclear neutrophils**
A. Alvarez-Larrán, J. Petriz, A. Martínez, C. Sanz and A. Pereira

135 **Fcγ receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura**
M. D. Carcao, V. S. Blanchette, C. D. Wakefield, D. Stephens, J. Ellis, K. Matheson and G. A. Denomme

Short report 142 **Phenotypic and genetic analysis of a compound heterozygote for dys- and hypoprothrombinaemia**
S. Akhavan, M. Luciani, S. Lavoretano and P. M. Mannucci

TRANSPLANTATION

145 **Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukaemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction**
S. Lee, D.-W. Kim, B. Cho, Y.-J. Kim, Y.-L. Kim, J.-Y. Hwang, Y.-H. Park, H.-J. Shin, C.-Y. Park, W.-S. Min, H.-K. Kim and C.-C. Kim

154 **Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation**
K. S. Peggs, S. Verfuerth, S. D'Sa, K. Yong and S. Mackinnon

CORRESPONDENCE

166 **FGFR3 dysregulation and clinical outcome in myeloma**
T. Rasmussen, H. R. Hudlebusch, L. M. Knudsen and H. E. Johnsen

167 **Plasma exchange as a source of protein C for acute-onset protein C pathway failure**
P. M. Baker, D. M. Keeling and M. Murphy

168 **Parvovirus B19 infection and acute lymphoblastic leukaemia**
S. Savaşan and Ö. Özdeir

169 **Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease**
I. A. Jagroop and D. P. Mikhailidis

170 **t(4;14)(p16.3;q32) is strongly associated with a shorter survival in myeloma patients**
J. M. Winkler, P. R. Greipp and R. Fonseca

171 **Serum erythropoietin values and endogenous erythroid colony growth in erythrocytoses and essential thrombocythaemia**
F. Girodon, S. Hermouet, I. Dobo and P. Mossuz and le groupe de standardization des techniques de culture de progéniteurs hématopoïétiques

172 **BOOK REVIEWS**

174 **ANNOUNCEMENTS**

Volume 120, Issue 2, January-II 2003

IMAGES IN HAEMATOLOGY

175 **Candidal infection diagnosed on trephine biopsy sections**
D. M. Clark and V. M. Tringham

176 **Granulocytic sarcoma (chloroma) of the lung**
R. de Paz, M. A. Canales and F. Hernandez-Navarro

REVIEW

177 **The role of hydroxyurea in sickle cell disease**
C. Halsey and I. A. G. Roberts

GUIDELINE

187 **Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes**
D. Bowen, D. Culligan, S. Jowitt, S. Kelsey, G. Mufti, D. Oscier, J. Parker of the UK MDS Guidelines Group

HAEMATOLOGICAL MALIGNANCY

201 **Defective expression of the T-cell receptor-CD3 ζ chain in T-cell acute lymphoblastic leukaemia**
G. F. Torelli, R. Paolini, C. Tatarelli, A. Soriani, A. Vitale, A. Guarini, A. Santoni and R. Foa

209 **Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome to younger adults: a prospective study of risk-adapted therapy**
J. García-Suárez, I. Krsnik, E. Reyes, D. D. Miguel, N. Hernanz, M. Barr-Alí and C. Burgaleta

217 **Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma**
D. Zhu, C. H. Ottensmeier, M.-Q. Du, H. McCarthy and F. K. Stevenson

223 **A possible role for the loss of CD27–CD70 interaction in myelomagenesis**
Y. Katayama, A. Sakai, N. Oue, H. Asaoku, T. Otsuki, T. Shiomomura, R. Masuda, N. Hino, Y. Takimoto, F. Imanaka, W. Yasui and A. Kimura

235 **Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy**
N. Abildgaard, K. Brixen, J. E. Kristensen, E. F. Eriksen, J. L. Nielsen and L. Heickendorff

243 **Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia**
F. Vuillier, K. Maloum, E. K. Thomas, C. Magnac, G. Dumas, B. Payelle-Brogard, P. Oppezzo, G. Dighiero and D. Scott-Algara

251 **Novel translocations that disrupt the platelet-derived growth factor receptor β (PDGFRB) gene in BCR–ABL-negative chronic myeloproliferative disorders**
E. J. Baxter, S. Kulkarni, J.-L. Vizmanos, R. Jaju, G. Martinelli, N. Testoni, G. Hughes, Z. Salamanchuk, M. J. Calasanz, I. Lahortiga, C. F. Pocock, R. Dang, C. Fidler, J. S. Wainscoat, J. Boultwood and N. C. P. Cross

257 **Overexpression of complement receptors and related antigens on the surface of bone marrow mast cells in patients with systemic mastocytosis**
R. Núñez-López, L. Escribano, G.-H. Schernthaner, A. Prados, R. Rodríguez-González, B. Díaz-Agustín, A. López, A. Hauswirth, P. Valent, J. Almeida, P. Bravo and A. Orfao

266 **Early detection of meningeal localization in acute promyelocytic leukaemia patients with high presenting leucocyte count**
M. Breccia, I. Carmosino, D. Diverio, S. De Santis, M. S. De Propris, A. Romano, M. C. Petti, F. Mandelli and F. Lo-Coco

Short reports

271 **A novel fusion variant of the *MORF* and *CBP* genes detected in therapy-related myelodysplastic syndrome with t(10;16)(q22;p13)**
K. Kojima, K. Kaneda, C. Yoshida, H. Dansako, N. Fujii, T. Yano, K. Shinagawa, M. Yasukawa, S. fujita and M. Tanimoto

274 **Successful treatment of acute myelomonocytic leukaemia with *NUP98–HOXD11* fusion transcripts and monitoring of minimal residual disease**
K. Terui, J. Kitazawa, Y. Takahashi, C. Tohno, Y. Hayashi, T. Taketani, T. Taki and E. Ito

277 **Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients**
S. E. Low, J. M. Horsman, S. J. Walters, H. Hancock, P. Smith, D. Linch and B. W. Hancock

TRANSPLANTATION

281 **Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission**
L. C. Feinstein, B. M. Sandmaier, U. Hegenbart, P. A. McSweeney, D. G. Maloney, T. A. Gooley, M. B. Maris, T. R. Chauncey, B. Bruno, F. R. Appelbaum, D. W. Niederwieser and R. F. Storb

289 **Bone marrow transplantation for β-thalassaemia major: the UK experience in two paediatric centres**
S. E. Lawson, I. A. G. Roberts, P. Amrolia, I. Dokal, R. Szydlo and P. J. Darbyshire

296 **Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. Results of a Grupo Español de Síndromes Linfoproliferativos/Trasplante Autólogo de Médula Ósea phase II trial**
J. J. Lahuerta, C. Grande, J. Martínez-Lopez, J. de la Serna, R. Toscano, M. Cruz Ortiz, S. Larregla, E. Conde, J. D. Gonzalez-San Miguel, J. Bargay, R. Cabrera, J. C. García-Ruiz, C. Albó, L. García-Alonso, F. Solano, P. Vivancos, A. León and J. San Miguel for the Grupo Español de Síndromes Linfoproliferativos/ Trasplante Autólogo de Médula Ósea

Short report

304 **Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma**
M. Kami, T. Hamaki, S. Miyakoshi, N. Murashige, Y. Kanda, R. Tanosaki, Y. Takaue, S. Taniguchi, H. Hirai, K. Ozawa and M. Kasai

PLATELETS, HAEMOSTAIS AND THROMBOSIS

310 **Is the factor XIII 34Val/Leu polymorphism a protective factor for cerebrovascular disease?**
G. Endler, M. Funk, D. Haering, W. Lalouschek, W. Lang, M. Mirafzal, O. Wagner and C. Mannhalter

315 **The effects of chemotherapeutic agents on the regulation of thrombin on cell surfaces**
N. Paredes, L. Xu, L. R. Berry and A. K. C. Chan

Short report

325 **Anti-thymocyte globulin treatment of marrow aplasia associated with paroxysmal nocturnal haemoglobinuria (PNH) resulted in haematological improvement due to an expansion of the PNH clone**
W. C. Cheung, C. C. K. Lam and Y. L. Kwong

HAEMOPOIESIS AND LEUCOCYTES

329 **Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34$^+$ haematopoietic cells and may prevent telomere attrition after chemotherapy**
M. Szyper-Kravitz, O. Uziel, H. Shapiro, J. Radnay, T. Katz, J. M. Rowe, M. Lishner and M. Lahav

337 **HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines**
M. Vitale, A. Caruso, M. A. De Francesco, L. Rodella, L. Bozzo, E. Garrafa, M. Grassi, G. Gobbi, A. Cacchioli and S. Fiorentini

RED CELLS AND IRON

344 **Regulated expression of MUC1 epithelial antigen in erythropoiesis**
A. Rughetti, M. Biffoni, L. Pierelli, H. Rahimi, G. Bonanno, S. Barachini, I. Pellicciotta, C. Napoletano, E. Pescarmona, A. Del Nero, P. Pignoloni, L. Frati and M. Nuti

353 **Impact of disordered puberty on bone density in β-thalassaemia major**
B. K. Bielinski, P. J. Darbyshire, L. Mathers, N. J. Crabtree, J. M. W. Kirk, H. F. Stirling and N. J. Shaw

359 **Circadian variations of transferrin saturation levels in iron-overloaded patients: implications for the screening of C282Y-linked haemochromatosis**
A. Guillygomarc'h, J. Christian, M. Romain, Q. Vincent, D. Véronique and Y. Deugnier

Short report 364 **A novel 7·9 kb deletion causing α$^+$-thalassaemia in two independent families of Indian origin**
C. L. Harteveld, P. van Delft, P. W. Wijermans, M. C. Kappers-Klunne, J. Weegenaar, M. Losekoot and P. C. Giordano

CORRESPONDENCE

367 **Long haul flights and deep vein thrombosis: who is at risk?**
F. R. Rosendaal, H. R. Büller, P. Kesteven and W. D. Toff

368 **Reply to Rosendaal *et al***
R. Arya and A. T. Cohen

368 **Severe aplastic anaemia in a child with brachydactyly type C**
E. Svarch, J. Fernández, R. Pons, A. González, M. Warman and R. P. Gale

369 **Modified chop-chemotherapy plus rituximab for diffuse large B-cell lymphoma complicating ataxia-telangiectasia**
G. Rossi, M. Zecca, A. Marchi, P. D. Stefano, L. Sammarchi and F. Locatelli

372 ANNOUNCEMENT

Volume 120, Issue 3, February-I 2003

IMAGES IN HAEMATOLOGY

373 **May–Hegglin anomaly**
C.-c. So and K.-f. Wong

374 **Thrombocytopenia and abdominal mass**
C. Salvador-Osuna, N. Fernandez-Mosteirin and C. Zapater

REVIEWS

375 **Pyrimidine 5′ nucleotidase deficiency**
D. C. Rees, J. A. Duley and A. M. Marinaki

384 **Human herpesvirus 6: relevance of infection in the immunocompromised host**
D. A. Clark and P. D. Griffiths

HAEMATOLOGICAL MALIGNANCY

396 **A nitric oxide synthase inhibitor, N^G-nitro-L-arginine-methyl-ester, exerts potent antiangiogenic effects on plasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model**
S. Uneda, H. Hata, F. Matsuno, A. Nagasaki, N. Harada, Y. Mitsuya, H. Matsuzaki and H. Mitsuya

405 **Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients**
S. Galimberti, F. Morabito, F. Guerrini, G. A. Palumbo, A. Azzarà, M. Martino, E. Benedetti, F. Di Raimondo and M. Petrini

413 **Mobilization of $CD34^+$ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen**
C. L. Morris, E. Siegel, B. Barlogie, M. Cottler-Fox, P. Lin, A. Fassas, M. Zangari, E. Anaissie and G. Tricot

424 **Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes**
D. E. Horsman, I. Okamoto, O. Ludkovski, N. Le, L. Harder, J. Gesk, R. Siebert, M. Chhanabhai, L. Sehn, J. M. Connors and R. D. Gascoyne

434 **Abnormal expression of apoptosis-related genes in haematological malignancies: overexpression of MYC is poor prognostic sign in mantle cell lymphoma**
B. Nagy, T. Lundán, M. L. Larramendy, Y. Aalto, Y. Zhu, T. Niini, H. Edgren, A. Ferrer, J. Vilpo, E. Elonen, K. Vettenranta, K. Franssila and S. Knuutila

442 **Expression of co-stimulatory molecules on acute myeloid leukaemia blasts may effect duration of first remission**
A. Whiteway, T. Corbett, R. Anderson, I. Macdonald and H. G. Prentice

452 **Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia**
W. G. Wierda, M. M. Johnson, K.-A. Do, T. Manshouri, A. Dey, S. O'Brien, F. J. Giles, H. Kantarjian, D. Thomas, S. Faderl, S. Lerner, M. Keating and M. Albitar

457 **Overexpression of manganese superoxide dismutase promotes survival in cell lines after doxorubicin treatment**
A. Suresh, L. Guedez, J. Moreb and J. Zucali

464 **Mutational analysis of class III receptor tyrosine kinases (C-KIT, C-FMS, FLT3) in idiopathic myelofibrosis**
F. M. Abu-Duhier, A. C. Goodeve, R. S. Care, M. Gari, G. A. Wilson, I. R. Peake and J. T. Reilly

471 **Detection of human herpesvirus-8 in peripheral blood mononuclear cells from adult Japanese patients with multicentric Castleman's disease**
S. Yamasaki, T. Iino, M. Nakamura, H. Henzan, K. Ohshima, M. Kikuchi, T. Otsuka and M. Harada

Short reports

478 **Expansion of $CD8^+$ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma**
O. Katopodis, S.-N. Liossis, V. Viglis, A. Pouli, M.-A. Dimopoulos and P. P. Sfikakis

482 **Absence of SCL mutations in myeloid malignancies**
E. Delabesse, J. Li, S. Schnittger, W. Hiddemann and A. R. Green

484 **E2A–PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features**
R. Foa, A. Vitale, M. Mancini, A. Cuneo, C. Mecucci, L. Elia, R. Lombardo, G. Saglio, G. Torelli, L. Annino, G. Specchia, E. Damasio, A. Recchia, F. Di Raimondo, E. Morra, E. Volpe, A. Tafuri, P. Fazi, S. P. Hunger and F. Mandelli

488 **Common clonal T-cell origin in a patient with T-prolymphocytic leukaemia and associated cutaneous T-cell lymphomas**
C. Assaf, M. Hummel, E. Dippel, S. Schwartz, C. C. Geilen, L. Harder, R. Siebert, M. Steinhoff, C.-D. Klemke, E. Thiel, S. Goerdt, H. Stein and C. E. Orfanos

492 **Re-entry of tumour B cells into the cycle of somatic mutation and isotype switching in follicular lymphoma**
S. Shiokawa, T. Matsushima, I. Choi, Y. Abe, M. Shiratsuchi, Y. Suehiro, K. Muta, K. Ohshima and J. Nishimura

496 **Cell surface CD43 determination improves diagnostic precision in late B-cell diseases**
G. Jung, J.-C. Eisenmann, S. Thiébault and P. Hénon

TRANSPLANTATION

500 **Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation**
F. Cervantes, J.-C. Hernández-Boluda, J. Odriozola, M. Camós, L. Villalón, J.-A. Martínez-Climent, R. del Campo, J. García-Conde and E. Montserrat

505 ***In vivo* imaging studies of the effect of recipient conditioning, donor cell phenotype and antigen disparity on homing of haematopoietic cells to the bone marrow**
N. Askenasy and D. L. Farkas

516 **The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis**
H. Nishihira, K. Kato, K. Isoyama, T. A. Takahashi, S. Kai, S. Kato, M. Takanashi, N. Sato, H. Sato, K. Kitajima, T. Naoe and H. Saito

Short report 523 **Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis**
T. L. Kiss, D. Spaner, A. S. Daly, W. S. Hasegawa, J. H. Lipton, H. A. Messner and H. Chang

PLATELETS, HAEMOSTASIS AND THROMBOSIS

526 **Oral anticoagulants in the elderly**
P. Froom, E. Miron and M. Barak

Short report 529 **Paradoxical association between the 316 Trp to Ser beta 2-glycoprotein I (Beta2GPI) polymorphism and anti-Beta2GPI antibodies**
M. J. Nash, R. S. Camilleri, R. Liesner, I. J. Mackie, S. J. Machin and H. Cohen

RED CELLS AND IRON

Short report 532 **L-arginine levels are diminished in adult acute vaso-occlusive sickle cell crisis in the emergency department**
B. L. Lopez, A. A. Kreshak, C. R. Morris, L. Davis-Moon, S. K. Ballas and X.-l. Ma

TRANSFUSION

535 **Hemolink™, an *o*-raffinose cross-linked haemoglobin-based oxygen carrier, does not affect activation and function of human platelets in whole blood *in vitro***
V. Leytin, D. Mazer, M. Mody, B. Garvey and J. Freedman

CORRESPONDENCE

542 **Gata-1 transcription factor is mutated in CMK megakaryoblastic cell line**
S. Kunishima, T. Kojima, C. Inoue, T. Kamiya and H. Saito
543 **The optimal management of polycythaemia vera**
M. F. McMullin, D. Bareford, J. Craig, A. R. Green, C. Harrison, D. G. Oscier and J. T. Reilly on behalf of the Myeloproliferative Disorders (MPD) (UK) Study Group
544 **Reply to McMullin *et al***
J. L. Spivak
546 **ERRATUM**

Volume 120, Issue 4, February-II 2003

IMAGES IN HAEMATOLOGY

547 **Cerebellar involvement in anaplastic large cell lymphoma**
D. E. Howarth, P. R. Kelsey and M. P. Macheta
548 **Chronic myelomonocytic leukaemia (CMML) presenting as a thyroid mass**
A. Adair, J. Parker and D. S. Coombes

HISTORICAL REVIEW

549 **A History of St Jude Children's Research Hospital**
J. V. Simone

GUIDELINES

556 **Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias**
S. L. Allford, B. J. Hunt, P. Rose and S. J. Machin on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology
574 **Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy**
British Committee for Standards in Haematology General Haematology Task Force

PLATELETS, HAEMOSTASIS AND THROMBOSIS

597 **Diagnosis of thrombotic thrombocytopenic purpura based on modulation by patient plasma of normal platelet adhesion under flow condition**
B. Shenkman, A. Inbal, I. Tamarin, A. Lubetsky, N. Savion and D. Varon

605 **A peptide (P2) derived from the variable heavy chain of an anti-P-selectin monoclonal antibody (LYP20) inhibits leucocyte adhesion to thrombin-activated platelets and endothelial cells**
J. F. Murphy and J. L. McGregor

611 **Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina**
G. T. Gerotziafas, A. Zafiropoulos, P. Van Dreden, E. Karavaggeli, N. Goutzoumas, P. Nikolaidis, C. Combot, P. Lagoudaki, K. Zervas, P. Arzoglou and M. M. Samama

618 **Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome**
C. J. Bidot, W. Jy, L. L. Horstman, H. Huisheng, J. J. Jimenez, M. Yaniz and Y. S. Ahn

627 **Two novel mutations, Q1053H and C1060R, located in the D3 domain of von Willebrand factor, are responsible for decreased FVIII-binding capacity**
L. Hilbert, S. Jorieux, V. Proulle, R. Favier, J. Goudemand, A. Parquet, D. Meyer, E. Fressinaud, C. Mazurier and the INSERM Network on Molecular Abnormalities in von Willebrand Disease

633 **Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADP**
J. O. Contreres, E. Dupuy, B. Job, A. Habib, M. Bryckaert, J. P. Rosa, G. Simoneau, J. M. Herbert, P. Savi and S. Levy-Toledano

643 **A new mutation, S1285F, within the A1 loop of von Willebrand factor induces a conformational change in A1 loop with abnormal binding to platelet GPIb and botrocetin causing type 2M von Willebrand disease**
A. Stepanian, A. S. Ribba, J. M. Lavergne, E. Fressinaud, I. Juhan-Vague, C. Mazurier, J. P. Girma and D. Meyer

Short reports

652 **Glycoprotein Ib polymorphisms influence platelet plug formation under high shear rates**
P. Jilma-Stohlawetz, M. Homoncik, B. Jilma, M. Knechtelsdorfer, P. Unger, C. Mannhalter, S. Santoso and S. Panzer

656 **Molecular pathology of haemophilia B in Turkish patients: identification of a large deletion and 33 independent point mutations**
U. Venüs Onay, K. Kavakli, Y. Kilinç, A. Gürgey, G. Aktuğlu, S. Kemahli, U. Özbek and S. Hande Çağlayan

HAEMATOLOGICAL MALIGNANCY

660 **Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group Experience**
M. S. Cairo, R. Sposto, S. L. Perkins, A. T. Meadows, M. L. Hoover-Regan, J. R. Anderson, S. E. Siegel, M. A. Lones, N. Tedeschi-Blok, M. E. Kadin, C. R. Kjeldsberg, J. F. Wilson, W. Sanger, E. Morris, M. D. Krailo and J. L. Finlay

671 **Leucocyte-specific protein (LSP1) in malignant lymphoma and Hodgkin's disease**
T. Marafioti, L. Jabri, K. Pulford, P. Brousset, D. Y. Mason and G. Delsol

679 **A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia**
S. B. Killick, G. Mufti, J. D. Cavenagh, A. Mijovic, J. L. Peacock, E. C. Gordon-Smith, D. T. Bowen and J. C. W. Marsh

685 **Long-term follow-up of granulocyte colony-stimulating factor receptor mutations in patients with severe congenital neutropenia: implications for leukaemogenesis and therapy**
P. J. Ancliff, R. E. Gale, R. Liesner, I. Hann and D. C. Linch

Short reports

691 **Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder**
A. Pardanani, T. K. Kimlinger, T. L. Reeder, C.-Y. Li and A. Tefferi

695 **Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12**
G. Pruneri, F. Bertolini, L. Baldini, S. Valentini, M. Goldaniga, D. Soligo, N. Carboni, G. Viale and G. Lambertenghi-Deliliers

699 **Neutropenia and anaemia associated with T-cell large granular lymphocyte leukaemia responds to fludarabine with minimal toxicity**
A. Sternberg, H. Eagleton, N. Pillai, K. Leyden, S. Turner, D. Pearson, T. Littlewood and C. Hatton

TRANSPLANTATION

702 **Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation**
J.-H. Lee, J.-H. Lee, S.-J. Choi, S. Kim, M. Seol, S.-W. Kwon, C.-J. Park, H.-S. Chi, J.-S. Lee, W.-K. Kim and K.-H. Lee

711 **Residual leukaemia after bone marrow transplant in children with acute lymphoblastic leukaemia after first haematological relapse or with poor initial presenting features**
N. Bunin, D. A. Johnston, W. M. Roberts, M. V. Ouspenskaia, V. Z. Papusha, M. A. Brandt and T. F. Zipf

CORRESPONDENCE

716 **Heterozygotes in the Bernard–Soulier syndrome do not necessarily have giant platelets or thrombocytopenia**
A. T. Nurden, R. Combrié, S. Claeyssens and P. Nurden

717 **What is the role of cytogenetic and molecular genetic analysis in the diagnosis of chronic myeloproliferative disorders?**
R. G. Owen, H. Dickinson, P. A. S. Evans, S. J. M. O'Connor, D. M. Swirsky and A. S. Jack

719 **Reply to Owen *et al***
G. Damaj and O. Hermine

720 **BOOK REVIEW**

721 **ANNOUNCEMENT**

722 **ERRATUM**

Volume 120, Issue 5, March-I 2003

IMAGES IN HAEMATOLOGY

723 **Bone marrow manifestation of Lyme disease (Lyme Borreliosis)**
H. M. Kvasnicka, J. Thiele and T. Ahmadi

724 **Intramedullary abscess in a patient with disseminated *Scedosporium apiospermum* infection**
T. Fietz, W. Knauf, S. Schwartz and E. Thiel

REVIEWS

725 **Therapeutic challenges in childhood sickle cell disease Part 1: current and future treatment options**
P. J. Amrolia, A. Almeida, C. Halsey, I. A. G. Roberts and S. C. Davies
737 **Therapeutic challenges in childhood sickle cell disease Part 2: a problem-orientated approach**
P. J. Amrolia, A. Almeida, S. C. Davies and I. A. G. Roberts

GUIDELINE

744 **Guidelines for the management of the acute painful crisis in sickle cell disease**
D. C. Rees, A. D. Olujohungbe, N. E. Parker, A. D. Stephens, P. Telfer and J. Wright

HAEMATOLOGICAL MALIGNANCY

753 **Endothelial stimulation by small lymphocytic lymphoma correlates with secreted levels of basic fibroblastic growth factor**
L. Rimsza, K. Pastos, J. Massey and R. Braylan
759 **Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients**
N. Parry-Jones, E. Matutes, A. M. Gruszka-Westwood, G. J. Swansbury, A. C. Wotherspoon and D. Catovsky
765 **Upregulation of CXCR1 by proliferating cells in patients with lymphoproliferative disease of granular lymphocytes**
R. Zambello, L. Trentin, M. Facco, D. Carollo, A. Cabrelle, A. Tosoni, G. Cannas, L. Nicolardi, C. Agostini and G. Semenzato
774 **Acute basophilic leukaemia: eight unsuspected new cases diagnosed by electron microscopy**
L. Shvidel, D. Shaft, B. Stark, M. Shtalrid, A. Berrebi and P. Resnitzky
782 **Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism**
A. Solanilla, C. Grosset, P. Duchez, P. Legembre, V. Pitard, M. Dupouy, F. Belloc, J.-F. Viallard, J. Reiffers, J.-M. Boiron, L. Coulombel and J. Ripoche

Short reports

787 **Prognostic factors and outcome for children after second central nervous system relapse of acute lymphoblastic leukaemia**
E. C. Morris, G. Harrison, C. C. Bailey, I. M. Hann, F. G. Hill, B. E. S. Gibson, S. Richards and D. K. H. Webb for the Medical Research Council Childhood Leukaemia Working Party
790 **Extragastric mucosa-associated lymphoid tissue lymphoma showing the regression by *Helicobacter pylori* eradication therapy**
N. Arima and M. Tsudo

TRANSPLANTATION

793 **Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries**
E. Vandenberghe, C. Ruiz de Elvira, F. R. Loberiza, E. Conde, A. López-Guillermo, C. Gisselbrecht, F. Guilhot, J. M. Vose, K. van Biesen, J. D. Rizzo, D. D. Weisenburger, P. Isaacson, M. M. Horowitz, A. H. Goldstone, H. M. Lazarus and N. Schmitz

801 **Prospective evaluation of cell kinetics, yields and donor experiences during a single large-volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells**
C. D. Bolan, C. S. Carter, R. A. Wesley, Y. Y. Yau, A. J. Barrett, R. W. Childs, E. J. Read and S. F. Leitman

PLATELETS, HAEMOSTASIS AND THROMBOSIS

808 **A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation**
C. A. Ludlam, M. P. Smith, M. Morfini, A. Gringeri, E. Santagostino and G. F. Savidge

814 **DDAVP enhances the ability of blood monocytes to form rosettes with activated platelets by increasing the expression of P-selectin sialylated ligands on the monocyte surface**
A. Pereira, M. del Valle Onorato and C. Sanz

821 ***ADAMTS13* gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13**
G. Antoine, K. Zimmermann, B. Plaimauer, M. Grillowitzer, J.-D. Studt, B. Lämmle and F. Scheiflinger

Short report 825 **Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods**
A. Tripodi, C. Valsecchi, V. Chantarangkul, T. Battaglioli and P. M. Mannucci

HAEMOPOIESIS AND LEUCOCYTES

829 **Tumour necrosis factor-α transcription in transferrin-stimulated human blood mononuclear cells: is transferrin receptor involved in the signalling mechanism?**
M. Lopez, E. Rios, L. Schlesinger, M. Olivares, M. T. Nunez and C. Munoz

836 **Abnormal telomere metabolism in Fanconi's anaemia correlates with genomic instability and the probability of developing severe aplastic anaemia**
X. Li, F. Leteurtre, V. Rocha, P. Guardiola, R. Berger, M.-T. Daniel, M. H. Noguera, O. Maarek, G. L. E. Roux, P. de la Salmonière, P. Richard and E. Gluckman

Short reports 846 **Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase**
K. Mihara, C. Imai, E. Coustan-Smith, J. S. Dome, M. Dominici, E. Vanin and D. Campana

850 **Involvement of cytotoxic granules in the apoptosis of aplastic anaemia**
J. L. Xu, T. Nagasaka and N. Nakashima

RED CELLS AND IRON

853 **Pharmacokinetics and red cell utilization of $^{52}Fe/^{59}Fe$-labelled iron polymaltose in anaemic patients using positron emission tomography**
S. Beshara, J. Sörensen, M. Lubberink, V. Tolmachev, B. Långström, G. Antoni, B. G. Danielson and H. Lundqvist

860 **Relative importance of female-specific and non-female-specific effects on variation in iron stores between women**
J. B. Whitfield, S. Treloar, G. Zhu, L. W. Powell and N. G. Martin

867 ***De novo* deletion within the telomeric region flanking the human α globin locus as a cause of α thalassaemia**
V. Viprakasit, A. M. J. Kidd, H. Ayyub, S. Horsley, J. Hughes and D. R. Higgs

876 **Different levels of p38 MAP kinase activity mediate distinct biological effects in primary human erythroid progenitors**
T. C. P. Somervaille, D. C. Linch and A. Khwaja

887 **Haematological effects of the C282Y *HFE* mutation in homozygous and heterozygous states among subjects of northern and southern European ancestry**
E. Beutler, V. Felitti, T. Gelbart and J. Waalen

894 **ATP-dependent vesiculation in red cell membranes from different hereditary stomatocytosis variants**
E. J. H. Turner, H. G. Jarvis, M. C. Chetty, G. Landon, P. S. Rowley, M. M. Ho and G. W. Stewart

Short report 903 **High-dose cyclophosphamide does not eradicate paroxysmal nocturnal haemoglobinuria haematopoiesis in mice carrying a *Piga* gene mutation**
A. Schaefer, M. Jasinski and M. Bessler

CORRESPONDENCE

907 **Gene polymorphisms associated with diminished activity of 5,10-methylenetetrahydrofolate reductase do not explain the clinical manifestations of cobalamin deficiency**
R. Carmel and V. Pullarkat

909 **Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura**
S. Čulić

910 **Ca^{2+} ionophore-induced dendritic cell differentiation in a patient with defective Ca^{2+} ionophore-induced platelet aggregation**
M. Narita, M. Takahashi, I. Fuse and Y. Aizawa

911 **A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec®)**
A. Drummond, P. Micallef-Eynaud, W. S. Douglas, J. A. Murphy, I. Hay, T. L. Holyoake and M. W. Drummond

913 **Plasma protein Z deficiency is common in women with antiphospholipid antibodies**
M. D. McColl, A. Deans, P. Maclean, R. C. Tait, I. A. Greer and I. D. Walker

914 **Intensive triathlon training induces low peripheral $CD34^+$ stem cells**
P. Philip and S. Bermon

916 ANNOUNCEMENT

Volume 120, Issue 6, March-II 2003

IMAGES IN HAEMATOLOGY

917 **Palmodigital purpura as the only skin abnormality in myeloma-associated systemic amyloidosis**
F. S. Vella, B. Simone and S. Antonaci

918 **Extramedullary haemopoiesis in haemoglobin E/β-thalassaemia**
R. E. Hough, R. Kelly, R. Nakielny and D. A. Winfield

REVIEWS

919 **Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation**
E. G. Haarman, G.-J. L. Kaspers and A. J. P. Veerman

930 **Transient Leukaemia – a benign form of leukaemia in newborn infants with trisomy 21**
A. Zipursky

HISTORICAL REVIEW

939 **Di Guglielmo and his syndromes**
B. J. Bain

HAEMATOLOGICAL MALIGNANCY

944 **Cytogenetics of multiple myeloma: interpretation of fluorescence *in situ* hybridization results**
C. J. Harrison, H. Mazzullo, K. L. Cheung, G. Gerrard, G. R. Jalali, A. Mehta, D. G. Osier and K. H. Orchard

953 **Soluble urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra-bone marrow involvement in multiple myeloma patients**
G. M. Rigolin, A. Tieghi, M. Ciccone, L. Z. Bragotti, F. Cavazzini, M. D. Porta, B. Castagnari, R. Carroccia, G. Guerra, A. Cuneo and G. Castoldi

960 **A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences**
T. Nilsson, M. Höglund, S. Lenhoff, L. Rylander, I. Turesson, J. Westin, F. Mitelman and B. Johansson

970 **Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma**
I. Chau, M. Harries, D. Cunningham, M. Hill, P. J. Ross, C. D. Archer, A. R. Norman, A. Wotherspoon, D. M. Koh, K. Gill, M. Uzzell, Y. Prior and D. Catovsky

978 **Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype**
K. W. Song, P. Mollee, A. Keating and M. Crump

986 **Over-expression of short isoforms of Helios in patients with adult T-cell leukaemia/lymphoma**
K. Fujii, F. Ishimaru, K. Nakase, T. Tabayashi, T. Kozuka, K. Naoki, M. Miyahara, H. Toki, K. Kitajima, M. Harada and M. Tanimoto

990 **The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia**
L. Wang, K. Pearson, J. E. Ferguson and R. E. Clark

1000 **Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia**
M. Vollmer, L. Li, A. Schmitt, J. Greiner, P. Reinhardt, M. Ringhoffer, M. Wiesneth, H. Döhner and M. Schmitt

1009 **Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of *FLT3* internal tandem duplications**
M. Pallis, J. Turzanski, M. Grundy, C. Seedhouse and N. Russell

1017 **Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia**
E. D. Hsi, K. J. Kopecky, F. R. Appelbaum, D. Boldt, T. Frey, M. Loftus and M. A. Hussein

1026 **Demonstration of aberrant T-cell and natural killer-cell antigen expression in all cases of granular lymphocytic leukaemia**
W. G. Morice, P. J. Kurtin, P. J. Leibson, A. Tefferi and C. A. Hanson

1037 **A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life**
E. Hellström-Lindberg, N. Gulbrandsen, G. Lindberg, T. Ahlgren, I. M. S. Dahl, I. Dybedal, G. Grimfors, E. Hesse-Sundin, M. Hjorth, L. Kanter-Lewensohn, O. Linder, M. Luthman, E. Löfvenberg, G. Öberg, A. Porwit-MacDonald, A. Rådlund, J. Samuelsson, J. M. Tangen, I. Winquist and F. Wisloff for the Scandinavian MDS Group

Short reports

1047 **Infection – an underappreciated cause of bone pain in multiple myeloma**
R. Desikan, B. Barlogie, R. Sethi, A. Toor, D. Spoon, E. Angtuaco, R. Vanhemert, A. vijayaGopal, S. Singhal, J. Mehta, S. Jagannath, N. Munshi, M. Zangari, A. Fassas, G. Tricot and E. Anaissie

1051 **Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma**
L. F. Lincz, F. E. Scorgie, I. Kerridge, R. Potts, A. Spencer and A. Enno

1055 **High levels of hyaluronan production by a malignant lymphoma cell line with primary effusion lymphoma immunophenotype OHK**
H. Kuwabara, M. Yoneda, M. Nagai, H. Nishio, T. Tasaka, K. Suzuki and H. Mori

1058 **Leukaemic pulmonary infiltrates in adult acute myeloid leukaemia: a high-resolution computerized tomography study**
L. Potenza, M. Luppi, M. Morselli, S. Tonelli, N. D'Apollo, L. Facchini, P. Torricelli, G. Tazzioli, A. Saviola, P. Bresciani, G. Longo and G. Torelli

1062 **Aberrant *p15* gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations**
W. Y. Au, A. Fung, C. Man, S. K. Ma, T. S. Wan, R. Liang and Y. L. Kwong

PLATELETS, HAEMOSTASIS AND THROMBOSIS

1066 **Lack of association of β2-glycoprotein I polymorphisms Val247Leu and Trp316Ser with antiphospholipid antibodies in patients with thrombosis and pregnancy complications**
R. S. Camilleri, I. J. Mackie, S. E. Humphries, S. J. Machin and H. Cohen

1073 **Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study**
F. Lordick, M. Hentrich, T. Decker, M. Hennig, H. Pohlmann, R. Hartenstein and C. Peschel

1079 **Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis**
E. Bourgeois, M. T. Caulier, C. Delarozee, M. Brouillard, F. Bauters and P. Fenaux

CORRESPONDENCE

1089 **Screening strategies in C282Y-linked haemochromatosis**
E. Beutler, J. Waalen and V. Felitti

1090 **The dangers of iron overload in pyruvate kinase deficiency**
S. R. Marshall, P. W. G. Saunders, P. J. Hamilton and P. R. A. Taylor

1091 **Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate**
P. Rousselot, J. Larghero, E. Raffoux, F. Calvo, M. Tulliez, S. Giraudier and M. Rybojad

1093 **Successful combination of anti-CD33 antibody (gemtuzumab ozogamicin) and minimal conditioning before second allografting in recurrent acute myeloid leukaemia**
M. Hänel, C. Thiede, A. Helwig, G. Prange-Krex, J. Babatz, M. Haack, F. Kroschinsky, S. Fetscher G. Ehninger and M. Bornhäuser

1094 **Methylenetetrahydrofolate reductase 677CC normal genotype may protect against multiple myeloma**
K. Yanamandra, J. A. Bocchini Jr and T. F. Thurmon

1095 **Reply to Yanamandra *et al***
R. García-Sanz, M. I. González-Fraile and J. F. San Miguel

1097 AUTHOR AND KEYWORD INDEXES FOR VOLUME 120